ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Expression and Significance of Protein Arginine Methyltransferase 1 in the Serum of Patients with Diabetes Kidney Disease.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to investigate the expression levels and significance of Protein Arginine Methyltransferase 1 (PRMT1) in patients with diabetic kidney disease (DKD). Patients and Methods: 236 patients with Type 2 Diabetes Mellitus (T2DM) who were admitted to Hebei Provincial People's Hospital from October 2023 to May 2025 were enrolled in this study. According to the urinary albumin-creatinine ratio (UACR), they were divided into normal albuminuria group (D1), microalbuminuria group (D2) and macroalbuminuria group (D3). 93 healthy people undergoing routine examination during the same period served as normal control (NC). Collect clinical data, use Enzyme-Linked Immunosorbent Assay (ELISA) to detect serum PRMT1. Detection of glucose and lipid metabolism and renal function indicators were used to evaluate intergroup differences and explore the relationship between PRMT1 and DKD. Results: Serum PRMT1 level rose gradually from NC group to D1, D2 and D3 groups (P<0.05), in T2DM patients, there was a significant positive association between PRMT1 expression and UACR (P < 0.05). Multivariate logistic regression analysis demonstrated that elevated PRMT1 expression was independently associated with both early and clinical DKD, and receiver operating characteristic (ROC) analysis indicated PRMT1 had discriminative ability for DKD. Conclusion: Serum PRMT1 concentrations were significantly elevated in patients with DKD compared with those with type 2 diabetes without nephropathy and healthy individuals, and levels increased with advancing disease severity, which implies that PRMT1 could be a valuable diagnostic marker for DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.